Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Recruiting
Observational Study
Pediatric Non-alcoholic Fatty Liver Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 8 – 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 850 (estimated)
- Sponsor
- University Hospital, Ghent · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic. Secondary to increasing rates of obesity in children and adolescents, the prevalence of NAFLD has more than doubled in the last decades and is now the most common pediatric liver disease.
At present, lifestyle modification by dietary intervention and increasin…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Enrolled in the lifestyle management program for obesity in one of the participating centres
Exclusion Criteria:
* Syndromic obesity
* Evidence of liver disease of other causes (viral, auto-immune, genetic)
* Average daily alcohol consumption of \>20g/day
* Unvalid screening…
Contacts